Migraine Industry (7MM) - US, France, Germany, Italy, Spain, UK, and Japan

298 views

Published on

The Report “EpiCast Report: Migraine – Epidemiology Forecast to 2023″ by GlobalData is now available at RnRMarketResearch.com. Contact sales@rnrmarketresearch.com with “EpiCast Report: Migraine – Epidemiology Forecast to 2023″ in subject line and your contact details to purchase this report or get your questions answered.
Migraine is typically characterized by recurring headaches, throbbing pain on one side of the head along with one or more of the following symptoms: nausea; vomiting; and increased sensitivity to light, sound and smell (Bigal and Lipton, 2006). Because migraine is one of the most prevalent types of headache, there is a substantial economic and social burden associated with the condition worldwide, and it is therefore recognized as a high-priority public health problem by the World Health Organization (WHO) (Leonardi et al., 2005; Lusic, 2001). The Global Burden of Disease (GBD) study in 2010 ranks migraine as the first among the neurological disorders (Leonardi and Raggi, 2013).
Request Sample copy of this report @ http://www.rnrmarketresearch.com/contacts/request-sample?rname=149041 .
In 2023, It epidemiologists forecast that the total prevalent cases of migraine in the 7MM remained almost the same, with 75.83 million total prevalent cases in 2013 and 76.38 million total prevalent cases, with an annual growth rate (AGR) of 0.07% in the forecast period. Throughout the forecast period, the US will have the highest number of total prevalent cases of migraine, with 29.61 million total prevalent cases in 2013 and 31.13 million total prevalent cases in 2023.
It epidemiologists obtained total prevalence data for migraine from peer-reviewed journals and population-based studies in the respective markets and used consistent methodology to ensure comparability of results. Furthermore, It epidemiologists made a meaningful assumption that the ageand sex-specific total prevalence of migraine in the 7MM would remain constant throughout the forecast period because epidemiologic literature suggests relatively stable trends in the prevalence of migraine worldwide, thereby providing a realistic and meaningful forecast for the ageand sex-specific total prevalent cases of migraine in the 7MM.
Complete report is available @ http://www.rnrmarketresearch.com/epicast-report-migraine-epidemiology-forecast-to-2023-market-report.html . Read more on “EpiCast Report: Migraine – Epidemiology Forecast to 2023” report below.

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
298
On SlideShare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
2
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Migraine Industry (7MM) - US, France, Germany, Italy, Spain, UK, and Japan

  1. 1. EpiCast Report: Migraine – Epidemiology Forecast to 2023 by GlobalData Explore all reports for “ Neurology Therapeutics ” market @ http://www.rnrmarketresearch.com/reports/lifesciences/pharmaceuticals/therapeutics/neurologytherapeutics . © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441
  2. 2. EpiCast Report: Migraine – Epidemiology Forecast to 2023 Migraine is typically characterized by recurring headaches, throbbing pain on one side of the head along with one or more of the following symptoms: nausea; vomiting; and increased sensitivity to light, sound and smell (Bigal and Lipton, 2006). Because migraine is one of the most prevalent types of headache, there is a substantial economic and social burden associated with the condition worldwide, and it is therefore recognized as a high-priority public health problem by the World Health Organization (WHO) (Leonardi et al., 2005; Lusic, 2001). The Global Burden of Disease (GBD) study in 2010 ranks migraine as the first among the neurological disorders (Leonardi and Raggi, 2013). In 2023, It epidemiologists forecast that the total prevalent cases of migraine in the 7MM remained almost the same, with 75.83 million total prevalent cases in 2013 and 76.38 million total prevalent cases, with an annual growth rate (AGR) of 0.07% in the forecast period. Throughout the forecast period, the US will have the highest number of total prevalent cases of migraine, with 29.61 million total prevalent cases in 2013 and 31.13 million total prevalent cases in 2023. Inquire for Discount @ http://www.rnrmarketresearch.com/contacts/discount?rname=149041 . © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441
  3. 3. EpiCast Report: Migraine – Epidemiology Forecast to 2023 It epidemiologists obtained total prevalence data for migraine from peer-reviewed journals and population-based studies in the respective markets and used consistent methodology to ensure comparability of results. Furthermore, It epidemiologists made a meaningful assumption that the ageand sex-specific total prevalence of migraine in the 7MM would remain constant throughout the forecast period because epidemiologic literature suggests relatively stable trends in the prevalence of migraine worldwide, thereby providing a realistic and meaningful forecast for the ageand sex-specific total prevalent cases of migraine in the 7MM. Complete Report Available @ http://www.rnrmarketresearch.com/epicast-report-migraine-epidemiology-forecastto-2023-market-report.html . © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441
  4. 4. EpiCast Report: Migraine – Epidemiology Forecast to 2023 Scope •The Migraine EpiCast Report provides an overview of the risk factors, comorbidities, and global trends of migraine in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the total prevalent cases of migraine segmented by age (beginning at 18 years and ending at 80 years and older), sex, and the number of total prevalent cases of migraine with aura and without aura in these markets. •The migraine epidemiology report is written and developed by Mastersand PhD-level epidemiologists. •The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM. Buy a copy of report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=149041 . © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441
  5. 5. EpiCast Report: Migraine – Epidemiology Forecast to 2023 Reasons to buy •Develop business strategies by understanding the trends shaping and driving the global migraine market. •Quantify patient populations in the global migraine market to improve product design, pricing, and launch plans. •Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for migraine therapeutics in each of the markets covered. •Identify the number of migraine cases with aura and without aura. Request Sample copy of this report @ http://www.rnrmarketresearch.com/contacts/request-sample?rname=149041 . © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441
  6. 6. EpiCast Report: Migraine – Epidemiology Forecast to 2023 For more details contact Mr. Priyank Tiwari: sales@rnrmarketresearch.com / +18883915441 RnR Market Research RnRMarketResearch.com, an online repository of market research reports, offers in-depth analysis of over 5000 market segments. RnR Market Research library has syndicated reports by leading market research publishers across the globe. © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441

×